Use of nanodispersions in pharmaceutical end formulations
View Patent ↗A description is given of the use of a nanodispersion, which comprises (a) a membrane-forming molecule, (b) a coemulsifier and (c) a lipophilic component, in pharmaceutical end formulations, the nanodispersion being obtainable by (α) mixing the components (a), (b) and (c) until a homogeneous clear liquid is obtained, and (β) adding the liquid obtained in step (α) to the water phase of the pharmaceutical end formulations, steps (α) and (β) being carried out without any additional supply of energy. The nanodispersions used according to this invention are suitable as transport vehicles for pharmaceutical active agents.
1. A method of preparing a pharmaceutical formulation of a lipophilic pharmaceutical active agent in the form of an aqueous monodisperse nanodispersion having a Gaussian distribution, which steps consist essentially of
(α) mixing the components
(a) 0.1 to 30% by weight of a phospholipid,
(b) 1 to 50% by weight of a polyoxyethylene coemulsifier selected from the group consisting of polyethoxylated fatty alcohols, polyethoxylated fatty acids, polyethoxylated vitamin E derivatives, polyethoxylated lanolin and derivatives thereof, polyethoxylated fatty acid partial glycerides, polyethoxylated alkylphenols, and salts thereof, polyethoxylated fatty amines and fatty acid amides and polyethoxylated carbohydrates,
(c) 0.1 to 80% by weight of a lipophilic component which comprises a natural or synthetic or a partially synthetic C 4 –C 18 triglyceride and a lipophilic pharmaceutical active agent, in which aqueous nanodispersion any pharmaceutically active agent is lipophilic and is always present in component (c), and
(d) 0.63 to 14.2% by weight of ethanol, with the proviso that the sum of (a), (b), (c) and (d) is 100% by weight, in conventional stirring apparatus until a homogeneous clear liquid is obtained, and
(β) adding the liquid obtained in step (α) to a water phase, wherein (β) is carried out in the absence of high shear or cavitation forces, and wherein the particles in the nanodispersion have an average diameter <50 nm.
2. A method according to claim 1 , wherein the polyoxyethylene coemulsifier is selected from the group consisting of polyethoxylated fatty alcohols, polyethoxylated fatty acids, polyethoxylated vitamin E derivatives, polyethoxylated lanolin and derivatives thereof, polyethoxylated fatty acid partial glycerides, polyethoxylated alkylphenols, and salts thereof.
3. A method according to claim 1 , wherein step (α) is carried out in an anhydrous medium.
4. A method according to claim 1 wherein the nanodispersion comprises as component (a) a compound selected from the group consisting of a phospholipids, a hydrated or partially hydrated phospholipids, a lysophospholipid, and mixtures thereof.
5. A method according to claim 1 , wherein the aqueous monodisperse nanodispersion of a lipophilic pharmaceutical active agent is a liquid formulation in the form of an injectable solution, infusion solution, drops, spray, aerosol, emulsion, lotion, suspension, drinking solution, gargle or inhalant.
6. A method according to claim 1 , wherein the aqueous monodisperse nanodispersion of a lipophilic pharmaceutical active agent is a semisolid formulation in the form of an ointment, oil-in-water emulsion, water-in-oil emulsion, gel, lotion, foam, paste, suspension, ovula or plaster.
7. A method according to claim 1 , wherein the aqueous monodisperse nanodispersion of a lipophilic pharmaceutical active agent is a matrix- or membrane-controlled pharmaceutical application system in the form of an oros capsule, transdermal system or injectable microcapsule.
8. A method according to claim 1 , wherein the nanodispersion is present in the aqueous phase.
9. A method according to claim 1 , wherein the nanodispersion is present in the aqueous phase in a concentration of 0.01 to 100% by weight.